ScreenerHero
MRKMERCK Kommanditgesellschaft auf Aktien
XETRA · DE · Healthcare · Drug Manufacturers - Specialty & Generic · emdgroup.com
137.30EUR-0.54%Mkt Cap: 65.24B $P/E: 23.72

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.46BUSDP/E 37.1

Key Statistics

Company
Market Cap65.24B $
Enterprise Value75.17B $
Revenue (TTM)22.97B $
Gross Profit13.42B $
Net Income (TTM)2.83B $
Revenue/Share52.86 USD
Last Price137.30 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees62.1K
CountryDE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)23.72
P/E (Forward)15.52
PEG2.37
EV/EBITDA12.38
EV/Revenue3.27
P/S2.82
P/B1.97
EPS (TTM)5.83
EPS (Forward)8.84
52W Range
100.7076% of range148.80
52W High148.80 EUR
52W Low100.70 EUR
Profitability
Gross Margin58.51%
Oper. Margin13.86%
EBITDA Margin26.43%
Profit Margin12.36%
ROE9.12%
ROA5.06%
Growth
Revenue Growth3.40%
Earnings Growth-24.70%
Cash Flow & Leverage
Operating CF4.27B $
CapEx (TTM)2.13B $
FCF Margin12.46%
FCF Yield4.39%
Net Debt9.98B $
Net Debt/EBITDA1.64
Balance Sheet
Debt/Equity0.42
Current Ratio1.70
Quick Ratio0.99
Book Value/Sh69.58 EUR
Cash/Share7.202 EUR
Dividends
Fwd Div Rate2.200 EUR
Trail. Div Rate2.200 EUR
Div. Yield1.59%
5Y Avg Yield1.35%
Payout Ratio37.74%
Ex-Div DateApr 27, 2026
Pay Date—
Splits
Last Split2:1
Split DateJun 30, 2014
Analyst Consensus
Rating2.2 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)153.50 EUR
Upside (mean)+11.8%
Target Range135.00 EUR – 179.00 EUR
€135.00+11.8% to mean€179.00
# Analysts14
Ownership
Shares Out.129.24M
Float128.87M
Insiders0.00%
Institutions55.95%
Technical
SMA 50139.97 (-1.9%)
SMA 200124.73 (+10.1%)
Beta0.81
S&P 52W Chg18.16%
Avg Vol (30d)245.08K
Avg Vol (10d)228.99K
Technical Indicators
RSI (14)45.2
MACD-0.4365
MACD Signal0.4222
MACD Hist.-0.8586
BB Upper148.14 EUR
BB Middle141.46 EUR
BB Lower134.78 EUR
BB Width9.45%
ATR (14)3.245 EUR
Vol Ratio (20d)1.28x